ArticleJournal of orthopaedic surgery and research2025
The clinical outcomes of joint-preserving endoprosthesis reconstruction for primary sarcomas about the knee.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Postoperative periprosthetic fractures associated with compressive osseointegration: a systematic review of the Zimmer Biomet CompressArchives of orthopaedic and trauma surgery · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThe purpose of this study was to investigate the clinical outcomes of joint-preserving endoprosthesis reconstruction for primary sarcomas about the knee.
methodsA retrospective cohort study was conducted on 45 patients (21 males, 24 females) who underwent joint-preserving endoprosthesis reconstruction (JPER) for bone tumours about the knee between January 2009 and January 2023. The average age was 23.9 ± 15.1 years (range, 7-66 years) and the most common pathological type was osteosarcoma (34), followed by Ewing's sarcoma (5), adamantinoma (3), spindle cell sarcoma (2), and undifferentiated pleomorphic sarcoma (UPS, 1). There were 35 cases of tumors located in the femur and 10 cases located in the tibia. The oncological outcomes included local control, metastasis, progression-free survival, and overall survival. The functional outcomes were evaluated by the Musculoskeletal Tumour Society Score (MSTS-93).
results45 patients were included in this retrospective study, and no patient were lost in the follow-up. The mean follow-up time was 105.3 ± 44.6 months (range, 15-183 months). Five patients (11.1%) died in the last follow-up. Four patients had local recurrences, and the mean interval between the index procedure to local recurrence was 25.5 months (range, 4-36 months). The 5-year and 10-year overall survival rate was 91.2% (95% CI 82.5%-99.9%) and 86.2% (95% CI 74.3%-98.1%), respectively. The 5-year and 10-year progression-free survival rate was 85.5% (95% CI 74.9%-96.1%) and 81.5% (95% CI 69.3%-93.7%), respectively. The average MSTS-93 score was 93% (range, 70-100%). The overall survivorship of the JPER was 84.4% (38/45) at an average of 8.7 years follow-up. Failure mechanisms included 4 infections (57%), 2 local tumour progression (29%), and one structural failure (14%) according to Henderson classification.
conclusionsThe joint-preserving endoprosthesis reconstruction (JPER) is a reliable technique to reconstruct massive bone defects after primary sarcoma resection about the knee with acceptable oncological outcomes, function, and satisfaction. LEVEL OF EVIDENCE: Level IV therapeutic study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.